ABIONYX Pharma: Combined General Meeting of June 28, 2022
30 Juin 2022 - 06:00PM
Business Wire
Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible)
(Paris:ABNX), a new generation biotech company dedicated to the
discovery and development of innovative therapies for patients,
announces that all resolutions were voted in accordance with the
recommendations of the Board of Directors.
The Meeting renewed the mandate of Emmanuel HUYNH, who remains
Chairman of the Board of Directors and a member of the Audit and
Compensation Committees, as well as of the Scientific, Research and
Patents Committee. Cyrille Tupin's mandate as Director and Chief
Executive Officer is also renewed.
To date, the Board of Directors of ABIONYX Pharma is composed
of:
– Emmanuel HUYNH, Chairman of the Board of Directors
– Cyrille TUPIN, Chief Executive Officer
– Karen Noël
– Laura Coruzzi
– Christian Chavy
– Bpifrance Participations, represented by Olivier Martinez,
censor
The General Meeting also approved the share buyback program and
the continuation of the liquidity contract.
The minutes of the General Meeting and the results of the votes
by resolution are available on the Company's website in the General
Meetings section.
Next financial press release:
Cash position and activity update for Q2 2022, August 18,
2022
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220630005683/en/
NewCap Investor relations Louis-Victor Delouvrier Nicolas
Fossiez abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 94 98
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Août 2023 à Sept 2023
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Sept 2022 à Sept 2023
